ONO PHARMACEUTICAL CO., LTD.

May 11, 2017

Ono Pharmaceutical Co., Ltd. ("The Company") has announced its consolidated financial results ended March 31, 2017.

The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRSs").

This Annual Flash Report for the year ended March 31, 2017 (unaudited) is summary information extracted from the financial statements announced, and the financial statements and the figures contained herein are prepared for reference only for the convenience of readers outside Japan with certain modifications and reclassifications made from the original financial statements presented in Japanese language.

The translations of Japanese yen amounts into U.S. dollar amounts are included solely for the convenience of readers outside Japan using the rate of 112 to \$1, the approximate rate of exchange at March 31, 2017.

Amounts of less than one million yen and one thousand U.S. dollars have been rounded to the nearest million yen and one thousand U.S. dollars in the presentation of the accompanying consolidated financial statements.

Financial Highlights

Ono Pharmaceutical Co., Ltd. and Consolidated Subsidiaries

	Millions of yen				Thousands of US\$	
	Year ended March 31, 2016		Year ended March 31, 2017		Year ended March 31, 2017	
Revenue	¥	160,284	¥	244,797	\$	2,185,690
Profit (Owners of the parent compa	ny)	24,979		55,793		498,152
Total equity		476,255		524,211		4,680,456
Total assets		540,450		617,461		5,513,043 US\$
Basic earnings per share	¥	47.13	¥	105.27	\$	0.94
Diluted earnings per share	¥	47.13	¥	105.26	\$	0.94

(Note) The company conducted a stock split of common stocks at a ratio of 1:5 with an effective date of April 1, 2016. As for "Basic earnings per share" and "Diluted earnings per share", it is calculated assuming that the stock split was conducted at April 1, 2015.